DATASPARK/OOREDOO
29.6.2021 02:02:07 CEST | Business Wire | Press release
DataSpark has signed a multi-year strategic deal with communications giant, Ooredoo Group, to automate and standardise their group-wide network planning processes, optimise capital expenditure spending and deliver superior customer experience.
The agreement will see DataSpark introduce its state-of-the-art Smart Network Planning (SNP) product to help establish an advanced analytics platform and capability in network planning across all 10 Ooredoo Group operating companies around the world.
The SNP solution (also referred to as CAPEX Optimizer in some regions) will deliver cost and operational efficiencies for Ooredoo Group’s network expansion investments while ensuring that fast-evolving customer needs are always kept at the centre of decision making.
The product utilises advanced machine learning methodologies to forecast and anticipate network capacity and throughput ahead of time, enabling Ooredoo to direct its capital expenditure in a way that creates the most value for the end customer.
DataSpark Chief Operating Officer, Shaowei Ying, said the partnership is a testament to DataSpark’s ability to provide performance-driven analytics solutions for global telco providers.
“The SNP solution empowers Ooredoo’s operating companies to have an automated, data-driven and customer-centric approach to their radio network capacity planning. It leverages best-in-class technologies that DataSpark developed over the last decade to process data at scale and extract granular insights for decision optimisation,” said Mr Ying. “We welcome this landmark partnership with Ooredoo Group which represents a significant milestone. DataSpark, as part of NCS NEXT, will continue expanding telco-centric analytic solutions and collaborate with telecommunication clients globally.”
The SNP’s application for telcos is founded on several key factors including automated and cost-efficient network planning through customer experience, services and network metrics, and layered analytics to inform accurate network investment decisions.
Ooredoo Group Chief Technology and Information Officer, Nigel Thomas Byrne, said the company’s venture with DataSpark would help ensure visibility and standardisation into network planning activities across the Ooredoo Group. This will also help in sharing network planning best practices across the group and further strengthen the culture of data-driven decision making.
“The insights and recommendations delivered through DataSpark’s SNP solution will provide cost-optimisation and allow us to innovate with our networks, ultimately enhancing the customer experience,” said Mr Byrne. “Our mission to deliver superior service is predicated on high-performance network planning and capacity management, and SNP’s advanced analytics will help us make informed decisions to deliver on this goal.”
DataSpark’s mobility data products are designed to optimise telco network solutions for revenue growth and improve customer satisfaction. DataSpark empowers organisations with mobility intelligence to help maximise the value of their networks and save on capital investment spending. Existing telecommunication clients include Singtel, Optus, Advanced Info Service and Globe Telecom.
About DataSpark: DataSpark are leaders in processing large geospatial temporal mobility data to deliver intelligence on people and places using the highest data privacy standards. Understanding how people move, where they go and what they do enables organisations to make more informed decisions from planning capital expenditure to creating better customer experiences. DataSpark (known as DSpark in Australia) is part of the NCS Group with offices across Australia, Singapore, the Philippines, and Indonesia. For more information, visit dsanalytics.com .
About NCS: NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of applications, infrastructure and engineering. For more information, visit ncs.com.sg .
About Ooredoo: Ooredoo is a leading international communications company delivering mobile, fixed, broadband internet and corporate managed services tailored to the needs of consumers and businesses across markets in the Middle East, North Africa and Southeast Asia. For more information, visit ooredoo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom